Published in Schizophr Bull on December 03, 2009
The neuroanatomical basis of panic disorder and social phobia in schizophrenia: a voxel based morphometric study. PLoS One (2015) 1.39
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry (2014) 1.39
Roles for pituitary adenylate cyclase-activating peptide (PACAP) expression and signaling in the bed nucleus of the stria terminalis (BNST) in mediating the behavioral consequences of chronic stress. J Mol Neurosci (2010) 1.36
Examining potential contraindications for prolonged exposure therapy for PTSD. Eur J Psychotraumatol (2012) 1.31
Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol (2012) 1.19
Deletion of densin-180 results in abnormal behaviors associated with mental illness and reduces mGluR5 and DISC1 in the postsynaptic density fraction. J Neurosci (2011) 1.07
Symptom dimensions and functional impairment in early psychosis: more to the story than just negative symptoms. Schizophr Res (2013) 1.02
The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders. Schizophr Bull (2011) 0.98
Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment. Adv Med (2014) 0.97
Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors. Front Pharmacol (2013) 0.97
Long Noncoding RNA-Directed Epigenetic Regulation of Gene Expression Is Associated With Anxiety-like Behavior in Mice. Biol Psychiatry (2015) 0.86
Traumatic Stress Disorders and Risk of Subsequent Schizophrenia Spectrum Disorder or Bipolar Disorder: A Nationwide Cohort Study. Schizophr Bull (2016) 0.86
Psychiatric comorbidity among adults with schizophrenia: a latent class analysis. Psychiatry Res (2013) 0.85
Changes in comorbid conditions after prolonged exposure for PTSD: a literature review. Curr Psychiatry Rep (2015) 0.83
A composite scale applied to evaluate anxiety in schizophrenic patients (SAES). Eur Arch Psychiatry Clin Neurosci (2013) 0.82
LRRTM1-deficient mice show a rare phenotype of avoiding small enclosures--a tentative mouse model for claustrophobia-like behaviour. Behav Brain Res (2012) 0.81
Stable cognitive deficits in schizophrenia patients with comorbid obsessive-compulsive symptoms: a 12-month longitudinal study. Schizophr Bull (2012) 0.81
Differential diagnosis of obsessive-compulsive symptoms from delusions in schizophrenia: A phenomenological approach. World J Psychiatry (2013) 0.80
Neuropsychological functions and visual contrast sensitivity in schizophrenia: the potential impact of comorbid posttraumatic stress disorder (PTSD). Front Psychol (2013) 0.79
Trauma-Focused Treatment in PTSD Patients With Psychosis: Symptom Exacerbation, Adverse Events, and Revictimization. Schizophr Bull (2015) 0.79
Alterations in spatial memory and anxiety in the MAM E17 rat model of hippocampal pathology in schizophrenia. Psychopharmacology (Berl) (2015) 0.78
Schizophrenia and Suicide Attempts: Findings from a Representative Community-Based Canadian Sample. Schizophr Res Treatment (2016) 0.78
A polymorphism in the dysbindin gene (DTNBP1) associated with multiple psychiatric disorders including schizophrenia. Behav Brain Funct (2010) 0.78
Anxiety in youth at clinical high risk for psychosis. Early Interv Psychiatry (2015) 0.77
Amygdala Hyperactivity in MAM Model of Schizophrenia is Normalized by Peripubertal Diazepam Administration. Neuropsychopharmacology (2016) 0.77
Prevalence and clinical characteristics of patients with obsessive-compulsive disorder in first-episode psychosis. BMC Psychiatry (2013) 0.77
Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia. J Psychiatry Neurosci (2015) 0.77
Associations of attention-deficit/hyperactivity and other childhood disorders with psychotic experiences and disorders in adolescence. Eur Child Adolesc Psychiatry (2016) 0.77
Cognitive alexithymia is associated with the degree of risk for psychosis. PLoS One (2015) 0.76
Uncovering obsessive-compulsive disorder risk genes in a pediatric cohort by high-resolution analysis of copy number variation. J Neurodev Disord (2016) 0.76
Obsessive-compulsive disorder for ICD-11: proposed changes to the diagnostic guidelines and specifiers. Rev Bras Psiquiatr (2014) 0.76
Frequent Comorbidity and Predictors of Social Anxiety in Persons With Schizophrenia: A Retrospective Cohort Study. Prim Care Companion CNS Disord (2015) 0.76
Schizophrenia comorbid with panic disorder: evidence for distinct cognitive profiles. Psychiatry Res (2012) 0.76
Hallucinations as a trauma-based memory: implications for psychological interventions. Front Psychol (2015) 0.76
Psychological Interventions for Working with Trauma and Distressing Voices: The Future Is in the Past. Front Psychol (2017) 0.75
Evidence for a Shared Etiological Mechanism of Psychotic Symptoms and Obsessive-Compulsive Symptoms in Patients with Psychotic Disorders and Their Siblings. PLoS One (2015) 0.75
Evidence from paranoid schizophrenia for more than one component of theory of mind. Front Psychol (2015) 0.75
Exon-focused genome-wide association study of obsessive-compulsive disorder and shared polygenic risk with schizophrenia. Transl Psychiatry (2016) 0.75
Early Psychosis and Trauma-Related Disorders: Clinical Practice Guidelines and Future Directions. Front Psychiatry (2017) 0.75
Densin-180 Controls the Trafficking and Signaling of L-Type Voltage-Gated Cav1.2 Ca(2+) Channels at Excitatory Synapses. J Neurosci (2017) 0.75
Severity of psychotic episodes in predicting concurrent depressive and anxiety features in acute phase schizophrenia. BMC Psychiatry (2014) 0.75
Posttraumatic Stress Disorder Symptoms and Social and Occupational Functioning of People With Schizophrenia. J Nerv Ment Dis (2016) 0.75
Preceding diagnoses to young adult bipolar disorder and schizophrenia in a nationwide study. BMC Psychiatry (2013) 0.75
Case report of visual hallucinations in anxiety. Shanghai Arch Psychiatry (2015) 0.75
Cardiac Coherence Training to Reduce Anxiety in Remitted Schizophrenia, a Pilot Study. Appl Psychophysiol Biofeedback (2016) 0.75
Large-scale interaction effects reveal missing heritability in schizophrenia, bipolar disorder and posttraumatic stress disorder. Transl Psychiatry (2017) 0.75
Prevalence of comorbid anxiety disorders in schizophrenia. Ind Psychiatry J (2017) 0.75
Associations between comorbid anxiety, diabetes control, and overall medical burden in patients with serious mental illness and diabetes. Int J Psychiatry Med (2015) 0.75
Biofeedback to treat anxiety in young people at clinical high risk for developing psychosis. Early Interv Psychiatry (2016) 0.75
Selective Mitochondrial Targeting Exerts Anxiolytic Effects In Vivo. Neuropsychopharmacology (2015) 0.75
Narrowing the focus on the assessment of psychosis-related PTSD: a methodologically orientated systematic review. Eur J Psychotraumatol (2016) 0.75
Longitudinal Associations between Posttraumatic Stress Disorder Severity and Personality Disorder Features among Female Rape Survivors. Front Psychiatry (2017) 0.75
Posttraumatic Stress Symptoms and Their Association With Smoking Outcome Expectancies Among Homeless Smokers in Boston. Nicotine Tob Res (2015) 0.75
Exposing therapists to trauma-focused treatment in psychosis: effects on credibility, expected burden, and harm expectancies. Eur J Psychotraumatol (2016) 0.75
Cross Talk: The Microbiota and Neurodevelopmental Disorders. Front Neurosci (2017) 0.75
Integrated Trauma-Focused Cognitive-Behavioural Therapy for Post-traumatic Stress and Psychotic Symptoms: A Case-Series Study Using Imaginal Reprocessing Strategies. Front Psychiatry (2017) 0.75
Transdiagnostic neural markers of emotion-cognition interaction in psychotic disorders. J Abnorm Psychol (2016) 0.75
Pathways from Trauma to Psychotic Experiences: A Theoretically Informed Model of Posttraumatic Stress in Psychosis. Front Psychol (2017) 0.75
The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry (1998) 65.11
The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry (1989) 16.61
The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry (1989) 6.80
Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry (1996) 5.71
Reliability of DSM-IV anxiety and mood disorders: implications for the classification of emotional disorders. J Abnorm Psychol (2001) 4.53
Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry (2006) 2.79
Psychiatric comorbidities and schizophrenia. Schizophr Bull (2008) 2.69
The prevalence of comorbid anxiety in schizophrenia, schizoaffective disorder and bipolar disorder. Aust N Z J Psychiatry (1998) 2.44
Social anxiety in outpatients with schizophrenia: a relevant cause of disability. Am J Psychiatry (2004) 2.18
The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry (2005) 2.03
How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull (2007) 1.87
Obsessive compulsive symptoms in schizophrenia: frequency and clinical features. Schizophr Res (2005) 1.75
Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder. Am J Psychiatry (1997) 1.67
Panic attacks in chronic schizophrenia. Br J Psychiatry (1990) 1.46
Obsessive-compulsive disorder in hospitalized patients with chronic schizophrenia. Psychiatry Res (2001) 1.36
Trauma and posttraumatic stress disorder in people with schizophrenia. J Abnorm Psychol (2003) 1.36
The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry (1986) 1.36
Exposure-based cognitive-behavioral treatment of PTSD in adults with schizophrenia or schizoaffective disorder: a pilot study. J Anxiety Disord (2009) 1.31
Posttraumatic stress disorder and service utilization among urban mental health center clients. J Trauma Stress (1999) 1.31
Obsessive-compulsive disorder in patients with first-episode schizophrenia. Am J Psychiatry (1999) 1.25
Obsessive-compulsive disorder in adolescent schizophrenia patients. Am J Psychiatry (2003) 1.18
Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs (2004) 1.16
Obsessions and compulsions as a distinct cluster of symptoms in schizophrenia: a neuropsychological study. J Nerv Ment Dis (1998) 1.12
Anxiety and schizophrenia: the interaction of subtypes of anxiety and psychotic symptoms. CNS Spectr (2005) 1.12
Trauma exposure and posttraumatic stress disorder in psychosis: findings from a first-admission cohort. J Consult Clin Psychol (2002) 1.10
Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life. J Psychiatr Res (2004) 1.08
Obsessive-compulsive disorder in schizophrenia. J Psychiatr Res (2000) 1.06
Hierarchical diagnosis in chronic schizophrenia: a clinical study of co-occurring syndromes. Schizophr Bull (2000) 1.04
Chronology of comorbid and principal syndromes in first-episode psychosis. Compr Psychiatry (1995) 1.00
Comorbidity in psychosis at first hospitalization. Am J Psychiatry (1993) 0.99
Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders. J Clin Psychiatry (1998) 0.97
Obsessive-compulsive and panic symptoms in patients with first-admission psychosis. Am J Psychiatry (2002) 0.96
Cognitive behavioural group treatment for social anxiety in schizophrenia. Schizophr Res (2003) 0.95
High rates of comorbidity are found in childhood-onset schizophrenia. Schizophr Res (2006) 0.94
Preliminary reliability and validity of the Clinician-Administered PTSD Scale for schizophrenia. J Consult Clin Psychol (2004) 0.94
Illness appraisals and self-esteem as correlates of anxiety and affective comorbid disorders in schizophrenia. Compr Psychiatry (2007) 0.92
Posttraumatic stress disorder symptoms related to psychosis and acute involuntary hospitalization in schizophrenic and delusional patients. J Nerv Ment Dis (1999) 0.92
The association between social anxiety and social functioning in first episode psychosis. Schizophr Res (2005) 0.91
Anxiety and substance use comorbidity among inpatients with schizophrenia. Schizophr Res (2003) 0.91
Schizophrenia: lifetime co-morbidity in a community sample. Acta Psychiatr Scand (1987) 0.89
Prevalence of obsessive-compulsive disorder in schizophrenia and significance of motor symptoms. J Neuropsychiatry Clin Neurosci (2000) 0.89
Prevalence and relationship to delusions and hallucinations of anxiety disorders in schizophrenia. Depress Anxiety (2003) 0.89
Obsessive-compulsive symptoms in schizophrenia: prevalance and clinical correlates. Psychiatry Clin Neurosci (2005) 0.87
Features of obsessive-compulsive disorder in patients primarily diagnosed with schizophrenia. Psychiatry Clin Neurosci (2003) 0.87
Obsessive-compulsive symptoms and positive, negative, and depressive symptoms in patients with recent-onset schizophrenic disorders. Can J Psychiatry (2005) 0.87
Psychiatric comorbidity in first episode psychosis: the Early Psychosis Intervention Program (EPIP) experience. Acta Psychiatr Scand (2004) 0.86
Involuntary admission and posttraumatic stress disorder symptoms in schizophrenia patients. Compr Psychiatry (1998) 0.86
Posttraumatic stress disorder, supported employment, and outcomes in people with severe mental illness. CNS Spectr (2004) 0.86
Psychiatric comorbidity in first episode schizophrenia: a 2 year, longitudinal outcome study. J Psychiatr Res (2006) 0.85
Obsessive-compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: a cause for clinical concern. J Psychopharmacol (2008) 0.85
Clinical features of panic attacks in schizophrenia. Eur Psychiatry (2001) 0.84
Prevalence and correlates of comorbidity 8 years after a first psychotic episode. Acta Psychiatr Scand (2007) 0.84
Comorbidity with axis I anxiety disorders in remitted psychotic patients 1 year after hospitalization. CNS Spectr (2007) 0.83
Measuring anxiety in patients with schizophrenia. J Nerv Ment Dis (2007) 0.83
Panic disorder in schizophrenia. Can J Psychiatry (1999) 0.82
Obsessive-compulsive disorder in elderly schizophrenia patients. J Psychiatr Res (2006) 0.82
[Frequency of obsessive compulsive symptoms and disorder in patients with schizophrenia: importence for prognosis]. Encephale (2006) 0.81
Panic symptoms in schizophrenia: comorbidity and clinical correlates. Psychiatry Clin Neurosci (2007) 0.81
Examination of comorbid anxiety in psychiatric inpatients. Compr Psychiatry (1991) 0.80
Panic attacks in patients with chronic schizophrenia: a complication of long-term neuroleptic treatment. Psychiatry Clin Neurosci (1999) 0.80
Sleep disturbances in childhood-onset schizophrenia. Schizophr Res (2006) 0.79
Neurological soft signs in schizophrenic patients with obsessive-compulsive disorder. Psychiatry Clin Neurosci (2004) 0.79
Obsessive compulsive disorder--prevalence in Xhosa-speaking schizophrenia patients. S Afr Med J (2005) 0.77
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol (2005) 7.12
Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol (2008) 5.98
Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA (2009) 4.71
Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov (2007) 4.27
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol (2009) 2.53
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol (2013) 2.46
The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med (2009) 2.45
Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol (2008) 2.01
Incidence and risk factors of insomnia in a population-based sample. Sleep (2009) 1.95
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res (2003) 1.88
Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol (2005) 1.80
Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther (2007) 1.74
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol (2007) 1.73
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol (2006) 1.67
Screening for PAX6 gene mutations is consistent with haploinsufficiency as the main mechanism leading to various ocular defects. Eur J Hum Genet (2003) 1.61
Quantifying dimensions in autism: a factor-analytic study. J Am Acad Child Adolesc Psychiatry (2002) 1.59
The brain through the retina: the flash electroretinogram as a tool to investigate psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry (2013) 1.57
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res (2003) 1.55
Retinal response to light in young nonaffected offspring at high genetic risk of neuropsychiatric brain disorders. Biol Psychiatry (2009) 1.53
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry (2004) 1.49
Fast, systematic, and continuous delirium assessment in hospitalized patients: the nursing delirium screening scale. J Pain Symptom Manage (2005) 1.47
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clin Cancer Res (2011) 1.39
Psychological and health-related quality of life factors associated with insomnia in a population-based sample. J Psychosom Res (2007) 1.39
Informative phenotypes for genetic studies of psychiatric disorders. Am J Med Genet B Neuropsychiatr Genet (2007) 1.35
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer (2012) 1.31
Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev (2013) 1.26
Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clin Cancer Res (2009) 1.18
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs (2007) 1.18
Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer Metastasis Rev (2013) 1.18
Psychoactive medications and risk of delirium in hospitalized cancer patients. J Clin Oncol (2005) 1.17
Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol (2007) 1.16
Prevalence of insomnia and its treatment in Canada. Can J Psychiatry (2011) 1.14
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs (2010) 1.09
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer (2010) 1.09
Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas. Oncotarget (2014) 1.08
Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev (2013) 1.08
Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag (2007) 1.07
Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol (2005) 1.07
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int (2012) 1.07
Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur J Cancer (2005) 1.05
Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells. Clin Cancer Res (2004) 1.05
Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Menopause (2009) 1.05
Opioid medications and longitudinal risk of delirium in hospitalized cancer patients. Cancer (2007) 1.04
Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells. Mol Cancer Ther (2011) 1.03
Preclinical and clinical development of novel agents that target the protein kinase C family. Semin Oncol (2006) 1.03
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs (2005) 1.01
Could we expect to improve survival in small cell lung cancer? Lung Cancer (2007) 1.00
Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem (2012) 1.00
Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res (2009) 0.99
A map of angular tuning preference in thalamic barreloids. J Neurosci (2003) 0.98
Decomposing the autism phenotype into familial dimensions. Am J Med Genet B Neuropsychiatr Genet (2008) 0.98
Long-acting injectable antipsychotics: evidence of effectiveness and use. Can J Psychiatry (2013) 0.97
Shared neurocognitive dysfunctions in young offspring at extreme risk for schizophrenia or bipolar disorder in eastern quebec multigenerational families. Schizophr Bull (2008) 0.97
Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection. Cancer (2012) 0.97
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist (2011) 0.97
Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat Rev (2008) 0.96
Global gene expression profiling of the polyamine system in suicide completers. Int J Neuropsychopharmacol (2011) 0.95
Profiling brain expression of the spermidine/spermine N1-acetyltransferase 1 (SAT1) gene in suicide. Am J Med Genet B Neuropsychiatr Genet (2009) 0.94
Regorafenib for metastatic colorectal cancer. Lancet (2013) 0.94
Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature. Hepatology (2014) 0.94
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol (2010) 0.93
Chromosome 13q13-q14 locus overlaps mood and psychotic disorders: the relevance for redefining phenotype. Eur J Hum Genet (2009) 0.93
Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. J Hepatol (2010) 0.93
Assessment of empathy in first-episode psychosis and meta-analytic comparison with previous studies in schizophrenia. Psychiatry Res (2010) 0.93
Family history of insomnia in a population-based sample. Sleep (2007) 0.91
Adiposity and eating behaviors in patients under second generation antipsychotics. Obesity (Silver Spring) (2008) 0.91
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med (2011) 0.91
Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. Mol Cancer Ther (2008) 0.91
Novel molecular therapies in hepatocellular carcinoma. Liver Int (2011) 0.91
Verbal and visual memory impairments among young offspring and healthy adult relatives of patients with schizophrenia and bipolar disorder: selective generational patterns indicate different developmental trajectories. Schizophr Bull (2010) 0.91
Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. J Clin Oncol (2009) 0.90
Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells. Mol Cancer Ther (2010) 0.90
Association between psychoactive medications and delirium in hospitalized patients: a critical review. Psychosomatics (2005) 0.90
Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr (2008) 0.90
Soft tissue sarcomas. Case 3. Gastrointestinal stromal tumor and Carney's triad. J Clin Oncol (2004) 0.90
Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer. Drug Saf (2009) 0.89
Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother Pharmacol (2005) 0.89
Impact on delirium detection of using a sensitive instrument integrated into clinical practice. Gen Hosp Psychiatry (2005) 0.88
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. Cancer Chemother Pharmacol (2013) 0.88
[Long-acting injectable antipsychotics: an expert opinion from the Association des médecins psychiatres du Québec]. Can J Psychiatry (2011) 0.88
Creation and pilot testing of StrokEngine: a stroke rehabilitation intervention website for clinicians and families. J Rehabil Med (2008) 0.87
Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin. Clin Cancer Res (2003) 0.87
Replication of linkage with bipolar disorder on chromosome 16p in the Eastern Quebec population. Am J Med Genet B Neuropsychiatr Genet (2008) 0.87
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol (2012) 0.87
Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment. Eur Arch Psychiatry Clin Neurosci (2013) 0.87
An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. Clin Schizophr Relat Psychoses (2013) 0.86
Gemcitabine in elderly patients with advanced pancreatic cancer. World J Gastroenterol (2011) 0.86